ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Lindley D, 1987. Merck‘s new drug free to WHO for river blindness program. Nature 329 :752.
-
2
Goa K, McTavish D, Clissold S, 1991. Ivermectin. A review of its antimicrofilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs 42 :640–658.
-
3
Remme J, Baker RHA, De Sole G, Dadzie KY, Walsh JF, Adams MA, Alley ES, Avissey HSK, 1989. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus.Trop Med Parasitol 40 :367–374.
-
4
Whitworth J, Morgan D, Maude G, Downham M, Taylor D, 1991. A community trial of ivermectin for onchocerciasis in Sierra Leone: adverse reactions after the first five treatment rounds. Trans R Soc Trop Med Hyg 85 :501–505.
-
5
Pacque M, Munoz B, Green BM, Taylor HR, 1991. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis 163 :381–385.
-
6
De Sole G, Remme J, Awadzi K, Accorsi S, Alley E, Ba O, Dadzie K, Giese J, Karam M, Keita F, 1989. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ 67 :707–719.
-
7
Ogunba E, Gemade E, 1992. Preliminary observations on the distribution of ivermectin in Nigeria for control of river blindness. Ann Trop Med Parasitol 86 :649–655.
-
8
Fischer P, Kipp W, Bamuhiiga J, Binta-Kahwa J, Kiefer A, Buttner DW, 1993. Parasitological and clinical characterization of Simulium neavei transmitted onchocerciasis in western Uganda. Trop Med Parasitol 44 :911–921.
-
9
Fischer P, Bamuhiiga J, Kilian A, Büttner DW, 1996. Strain differences of Onchocerca volvulus from Uganda using DNA probes. Parasitology 112 :401–408.
-
10
Fischer P, Kipp W, Kabwa P, Büttner D, 1995. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg 53 :171–178.
-
11
Njoo FL, Beek WM, Keukens HJ, van Wilgenburg H, Oosting J, Stilma JS, Kijlstra A, 1995. Ivermectin detection in serum of onchocerciasis patients: relations to adverse reactions. Am J Trop Med Hyg 52 :94–97.
-
12
Mwetta E, Hills E, 1994. Community treatment with ivermectin for onchocerciasis in the east Usambara mountains. East Afr Med J 71 :790–791.
-
13
Burnham G, 1993. Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi. Trans R Soc Trop Med Hyg 87 :313–317.
-
14
Kipp W, Burnham DG, Bamuhiiga J, Weis P, Buttner DW, 1998. Ivermectin distribution using community volunteers in Kabarole district, Uganda. Int J Health Policy Plann 13 :167–173.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 244 | 90 | 1 |
| PDF Downloads | 36 | 23 | 1 |
ADVERSE REACTIONS TO IVERMECTIN TREATMENT IN SIMULIUM NEAVEI–TRANSMITTED ONCHOCERCIASIS
To assess adverse effects of ivermectin treatment in a Simulium neavei-transmitted focus of onchocerciasis, a study was conducted with 1,246 patients infected with Onchocerca volvulus in eight villages in western Uganda. Study participants were treated the first time with a single dose of 150 μg/kg of ivermectin. Adverse reactions to ivermectin were determined through questioning and clinical examination during house-to-house visits to the participants within 48 hours after ivermectin treatment. Overall adverse reactions were observed in 737 (59.1%) patients. Severe reactions were rare (10 patients, 1.4%). Our data show that adverse reactions to ivermectin in an S. neavei-transmitted onchocerciasis focus in western Uganda occur frequently. In spite of the fact that many patients showed adverse reactions to ivermectin, the drug was well accepted and appreciated by the population.